Standard: this guide onlyAll-Access Lifetime: all 45 guides + downloadsEducational content only
Mod GRF 1-29 Guide: Available Now
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
Mod GRF 1-29 at a glance
What it is
A modified GHRH(1-29) analog (tetra-substituted sermorelin fragment) without the DAC albumin-binding tag; also called CJC-1295 no DAC or Modified GRF 1-29.
Researched for
Reported in research and community contexts for stimulating pulsatile growth-hormone (GH) release and downstream IGF-1; investigational, not an approved therapy.
Commonly reported range
~100 mcg per injection (the reported saturation dose); some protocols report 100-200 mcg, up to 300 mcg.
Route reported
Subcutaneous injection (research context).
Reported frequency
1-3 times daily, often before bed and/or post-fast on an empty stomach.
Reported cycle
Community-reported cycles of roughly 6-12 weeks.
Plasma half-life
Approximately 30 minutes (short-acting).
Regulatory status
Not FDA-approved; research-use-only. Prohibited in sport at all times by WADA (class S2).
Reported ranges from research/community — examples, not recommendations.
What it is / mechanism
Mod GRF 1-29 is a synthetic analog of the first 29 amino acids of growth-hormone-releasing hormone (GHRH), the shortest fully active fragment. It carries four amino-acid substitutions (positions 2, 8, 15 and 27) that were introduced to resist enzymatic cleavage by DPP-IV and reduce oxidation, improving stability over native sermorelin. Unlike CJC-1295 with DAC, it lacks the Drug Affinity Complex that binds serum albumin, so it does not accumulate in the bloodstream for days. Instead it binds pituitary GHRH receptors and triggers a short, pronounced burst of GH release that mimics the body's natural pulsatile pattern before clearing within roughly 30 minutes. Because of this short action, research protocols typically pair it with a GH secretagogue (ghrelin mimetic) such as ipamorelin to amplify each pulse.
Researched effects
In research and community reports, Mod GRF 1-29 is associated with transient increases in GH pulse amplitude and downstream IGF-1, and users describe outcomes such as improved sleep quality, changes in body composition and recovery. These are research findings and anecdotal community reports, not guaranteed outcomes; individual responses vary and human data specific to this exact analog are limited. It is designed to preserve the natural pulsatile rhythm of GH secretion rather than create the sustained elevation seen with the DAC-modified version.
Evidence & regulatory status
Evidence: Native GHRH(1-29) (sermorelin) and tetra-substituted GRF 1-29 analogs have been shown in pharmacology studies to stimulate pituitary GH secretion; most published human data cover sermorelin and the DAC variant rather than the exact no-DAC analog, so evidence for Mod GRF 1-29 specifically is largely preclinical and community-reported.
Regulatory: Not approved by the FDA for any indication and sold for research use only; it is prohibited in sport at all times under WADA class S2 (peptide hormones, growth factors and related substances).
Research use: All dosing figures here describe what is reported in the literature and community as examples for educational purposes; they are not medical recommendations, and this compound is not intended for human therapeutic use.
Dosage — reported ranges (overview)
The figures below are examples of what is reported in research and community protocols, not a recommendation. A frequently cited reference point is the ~100 mcg 'saturation dose', the point at which pituitary GHRH receptors are reported to be largely occupied and additional peptide yields diminishing returns. Reported protocols commonly describe 100-200 mcg per subcutaneous injection, one to three times daily, sometimes timed before bed or on an empty stomach to align with natural GH pulses; some report up to 300 mcg. Reported cycles run roughly 6-12 weeks.
The full step-by-step protocol examples, titration, and printable protocol sheet are planned for a future paid Protocol Playbook module.
Reconstitution — bac-water math
Mod GRF 1-29 ships as a lyophilized (freeze-dried) powder and is reconstituted with bacteriostatic water. Because it is dosed in micrograms (mcg), the key relationship is: concentration (mcg/mL) = (vial mg x 1000) / mL of water added. To find the dose in insulin-syringe units on a U-100 syringe (100 units = 1 mL): units = dose in mcg / concentration x 100. Worked example: a 5 mg vial reconstituted with 2 mL of bacteriostatic water gives (5 x 1000) / 2 = 2500 mcg/mL. A 100 mcg example dose is then 100 / 2500 x 100 = 4 units on a U-100 syringe. This is concentration math only, not a personal dose.
Bac water added
Concentration
100 mcg (low example)
200 mcg (high example)
1 mL
5000 mcg/mL
2 units
4 units
2 mL
2500 mcg/mL
4 units
8 units
3 mL
1667 mcg/mL
6 units
12 units
This is concentration math, not a dose recommendation.
Pre-fills example values. Every field remains editable.
The amount printed on the vial or listed on a product page.
mL
Liquid volume used for the concentration calculation.
The mass amount to convert into liquid volume for this math example.
4. Insulin syringe size
Your result
Syringe-unit reading
10 units
= 0.1 mL · 250 mcg target amount
Concentration
2.5mg/mL
Per insulin unit
25mcg
Portions per vial
20
Volume
0.1mL
This calculator is an educational tool for laboratory and research math only. The peptides referenced are research compounds not intended for human or veterinary use, and example values are not medical advice or personal-use instructions. Follow applicable research protocols and regulations.
How the calculator works
Concentration
peptide ÷ liquid
Total peptide divided by liquid volume gives the concentration per mL.
Volume
target ÷ concentration
The target mass divided by concentration gives the liquid volume.
Syringe units
volume × 100
For insulin units, 100 units equals 1 mL, so mL is multiplied by 100.
Worked example: A 5 mg vial plus 2 mL liquid creates a 2.5 mg/mL concentration. A 250 mcg target amount equals 0.1 mL, or 10 insulin units. The vial contains 20 such portions.
Frequently asked questions
How much bacteriostatic water should I enter?+
There is no single calculator-default amount. The liquid volume controls concentration: more liquid creates a less concentrated solution and a larger volume reading for the same target amount; less liquid creates a more concentrated solution and a smaller volume reading.
How do insulin syringe units relate to mL?+
For this math tool, 100 insulin units equals 1 mL, and 1 unit equals 0.01 mL. The 0.3 mL, 0.5 mL, and 1.0 mL options change capacity, not the unit-to-mL relationship.
What is the difference between mg, mcg, and units?+
Milligrams and micrograms measure peptide mass: 1 mg = 1,000 mcg. Syringe units measure liquid volume. Reconstitution math connects mass and volume by using concentration.
Does changing the liquid volume change the total peptide in the vial?+
No. The total peptide amount entered for the vial remains fixed. Changing the liquid volume only changes concentration and the resulting volume shown by the calculator.
Injection / administration basics
In research contexts, Mod GRF 1-29 is reconstituted with bacteriostatic water, drawn into a U-100 insulin syringe, and administered subcutaneously (into the fatty tissue of the abdomen, for example) using standard aseptic technique: swab the vial stopper and injection site with alcohol, expel air bubbles, and rotate sites. Reports frequently note dosing on an empty stomach, since food (especially carbohydrates and fats) and elevated blood sugar can blunt the GH response. This describes handling, not a recommendation to inject.
Half-life & frequency rationale
The plasma half-life is reported at roughly 30 minutes, making it short-acting. This brevity is intentional: it produces a discrete GH pulse and then clears, which is why protocols describe frequent dosing (up to three times daily) and pairing with a ghrelin-mimetic secretagogue rather than the sustained, multi-day elevation of the DAC-modified CJC-1295.
Side effects, safety & contraindications
Reported and theoretically expected effects for GHRH analogs include injection-site reactions (flushing, redness, itching), transient tingling or numbness, headache, water retention, increased appetite, and fatigue or head-rush if poorly timed. Elevations in cortisol and prolactin are considered less likely with selective GHRH/ipamorelin-type combinations than with older GHRPs but are noted as possibilities. Human safety data specific to this exact analog are limited, and long-term effects are not well characterized; anyone researching GH-axis peptides should be aware that sustained GH/IGF-1 elevation carries theoretical risks (e.g., insulin resistance, edema).
Stacking — overview
Mod GRF 1-29 is very commonly reported alongside a growth-hormone secretagogue (a ghrelin mimetic) because the two act on different receptors and are described as producing a synergistic GH pulse larger than either alone. The classic pairing is with Ipamorelin, typically at a matched 1:1 example dose. It is also reported stacked with tissue-repair and recovery peptides. All stacks below are examples of what is reported in the community, not recommendations.
GH Pulse Stack
Mod GRF 1-29 + Ipamorelin (commonly reported 1:1, e.g. 100 mcg each per injection)
Recovery / Repair Stack
Mod GRF 1-29 + Ipamorelin + BPC-157 + TB-500
CJC + GHRP Alternative
Mod GRF 1-29 + GHRP-2 or GHRP-6 (older-generation secretagogue pairing)
Skin & Connective Tissue Stack
Mod GRF 1-29 + Ipamorelin + GHK-Cu
Storage & handling
Lyophilized (powder): store refrigerated at 2-8C; keep away from light and heat. Long-term storage in a freezer is often reported to extend stability of the unreconstituted powder.
Reconstituted (in bacteriostatic water): keep refrigerated at 2-8C and use within roughly 28 days; do not freeze the reconstituted solution and avoid vigorous shaking.
References
Content synthesizes GHRH/sermorelin pharmacology literature, published data on the CJC-1295 (DAC and no-DAC) analog family, and community-reported protocols; figures are educational examples, not medical advice.
Related peptide guides
Continue exploring related educational guide topics in the Medibact library.
Quick answers about guide scope, access, and educational use context.
Is Mod GRF 1-29 the same as CJC-1295?
Mod GRF 1-29 is the same molecule as CJC-1295 without DAC (no Drug Affinity Complex). 'CJC-1295' on its own often refers to the DAC version, which binds albumin and lasts days rather than minutes. Mod GRF 1-29 is the short-acting no-DAC form.
Why is it dosed so frequently?
Its half-life is only about 30 minutes, so each injection produces a single short GH pulse. Research protocols report dosing one to three times daily to create multiple pulses that mimic the body's natural rhythm, rather than one sustained elevation.
What is the 'saturation dose'?
Community and research sources describe roughly 100 mcg as the saturation dose, the point at which the pituitary's GHRH receptors are reported to be largely occupied. Above this, additional peptide is said to give diminishing returns on GH release. This is a reported reference point, not a personal-dose recommendation.
Why is it often paired with ipamorelin?
Mod GRF 1-29 (a GHRH analog) and ipamorelin (a ghrelin-receptor secretagogue) act on separate pathways. Reports describe combining them to produce a synergistic GH pulse larger than either alone, typically at a 1:1 example dose.
Is it legal or approved?
It is not approved by the FDA for any use and is sold strictly for research purposes. It is also prohibited in sport at all times under WADA class S2. Nothing in this guide is medical advice or an endorsement of human use.
Compliance and trust notes
Educational content only; no personalized health or outcome claims.
No personalized use recommendation outputs.
Use this material for general learning and research-context literacy.
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
